681 filings
15-12B
Assertio Holdings Inc.
18 Jun 20
Securities registration termination
12:28pm
8-K
Assertio Holdings Inc.
22 May 20
Entry into a Material Definitive Agreement
5:05pm
25-NSE
The Nasdaq Stock Market LLC
19 May 20
Exchange delisting
4:40pm
DEFA14A
Assertio Holdings Inc.
18 May 20
Additional proxy soliciting materials
4:34pm
10-Q
2020 Q1
Assertio Holdings Inc.
Quarterly report
11 May 20
10:10am
8-K
vzq7 zdg0zpeyci
11 May 20
Assertio Therapeutics Announces First-Quarter 2020 Results
8:10am
425
uyexuosb9o
11 May 20
Business combination disclosure
8:06am
8-K
4v9dd 7xw
24 Apr 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
v45tz0iq42mkg2371
21 Apr 20
Merger with Zyla Life Sciences Expected to Close Shortly After the 2020 Annual Meeting
12:00am
425
4z7wzg 6i82xu3
21 Apr 20
Business combination disclosure
12:00am
SC TO-I/A
q6q0542qbgshonph4
8 Apr 20
Issuer tender offer statement (amended)
4:39pm
8-K
ne25ld230947o
8 Apr 20
Assertio Therapeutics Announces Completion and Final Results of the Offer to Purchase
4:34pm
SC TO-I/A
incf854hotiaox6ki
25 Mar 20
Issuer tender offer statement (amended)
6:06am
8-K
t9w929pa9p9h605
17 Mar 20
Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products
8:02am
425
es77nhfzhdl4p69
17 Mar 20
Business combination disclosure
8:00am
SC TO-I
z2tun35yjj72h
11 Mar 20
Issuer tender offer statement
7:52am
8-K
pcm21xzcu30zcazn0z
11 Mar 20
Assertio Therapeutics Announces Offer to Purchase
6:01am
8-K
hcsgsww2sz x0
9 Mar 20
Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2019 Financial Results
4:09pm